YC
ADPT icon

Yarbrough Capital’s Adaptive Biotechnologies ADPT Stock Holding History

Yarbrough Capital’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-28,563
Closed -$464K – 87
2025
Q4 		$464K Hold
28,563
– – 0.01% 119
2025
Q3 		$427K Buy
+28,563
New +$348K 0.01% 130

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Yarbrough Capital's ADPT Position: Q1 2026 in Review

Yarbrough Capital sold out of Adaptive Biotechnologies (ADPT) in Q1 2026, closing a stake of 28,563 shares — an estimated $464K sold.

Yarbrough Capital first reported a position in ADPT in Q3 2025 and held it in 2 quarters. The position peaked at $464K in Q4 2025. 295 funds tracked by Wall St. Rank hold ADPT as of Q1 2026.

  • Yarbrough Capital reported no remaining Adaptive Biotechnologies position as of Q1 2026 after selling out during the quarter.
  • Yarbrough Capital sold 28,563 Adaptive Biotechnologies shares in Q1 2026, an estimated $464K.
  • Yarbrough Capital first reported a position in Adaptive Biotechnologies in Q3 2025 and held it in 2 quarters.
  • Yarbrough Capital's Adaptive Biotechnologies position peaked at $464K in Q4 2025.
  • 295 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2026.

Based on Yarbrough Capital's 13F filing for Q1 2026, filed 14 Apr 2026.